Announce Phase 3 topline data for LNZ100/1
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 15 Nov 2023
- Due
- 30 Jun 2024
- Delivered
- April 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Ph3 topline 2Q24”
What we found
Evidence strength A What the grades mean
The company announced positive topline data from its Phase 3 CLARITY study for LNZ100 in April 2024, which is within the second quarter of 2024.
-
A LENZ Therapeutics, Inc. 8-K filed 2024-08-14
“In April 2024, LENZ reported positive topline data from its Phase 3 CLARITY study for the treatment of presbyopia.” ✓ confirmed on the page
Market reaction: the shares moved -4.1% against the S&P 500 over the three sessions around the disclosure (13 Aug 2024 to 16 Aug 2024). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Announce
- Deliverable
- Phase 3 topline data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you LENZ Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-LENZ-003358 · Corrections policy